Ocrevus
Author: Daniel Chancellor
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Ocrevus is a second-generation cluster of differentiation (CD)20 antibody. Similar to Roche’s blockbuster cancer drug Rituxan (rituximab), Ocrevus specifically targets CD20+ B cells, thus depleting lymphocytes that produce the autoimmune response. However, as a humanized version of rituximab, it is hypothesized to induce less immunogenicity. Ocrevus is now wholly owned by Roche, with former development partner Biogen entitled to royalties of its sales in the US.
Although Ocrevus has been previously investigated in rheumatoid arthritis, it is now specifically for use in MS. Ocrevus was first approved in the US for the treatment of relapsing and PPMS in March 2017, and remains under regulatory review in other regions.
TABLE OF CONTENTS
4 Product Profiles
4 Ocrevus : Multiple sclerosis (MS)
LIST OF FIGURES
8 Figure 32: Ocrevus for multiple sclerosis – SWOT analysis
9 Figure 2: Datamonitor Healthcare’s drug assessment summary for Ocrevus in multiple sclerosis
LIST OF TABLES
5 Table 1: Ocrevus drug profile
11 Table 48: Ponesimod Phase III trials in multiple sclerosis
12 Table 3: Ocrevus sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
ALKS 8700 
Sign up to the